JO2797B1 - Selective opioid receptor antagonist kappa - Google Patents

Selective opioid receptor antagonist kappa

Info

Publication number
JO2797B1
JO2797B1 JO200915A JOP20090015A JO2797B1 JO 2797 B1 JO2797 B1 JO 2797B1 JO 200915 A JO200915 A JO 200915A JO P20090015 A JOP20090015 A JO P20090015A JO 2797 B1 JO2797 B1 JO 2797B1
Authority
JO
Jordan
Prior art keywords
receptor antagonist
opioid receptor
selective opioid
kappa selective
kappa
Prior art date
Application number
JO200915A
Other languages
Arabic (ar)
English (en)
Inventor
دياز بوزو نوريا
لي ماكينزي ديفيد
هوارد ميتش شارلز
بيدريجال تيرسيرو كونسيبسيون
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2797B1 publication Critical patent/JO2797B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JO200915A 2008-01-22 2009-01-13 Selective opioid receptor antagonist kappa JO2797B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
JO2797B1 true JO2797B1 (en) 2014-03-15

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
JO200915A JO2797B1 (en) 2008-01-22 2009-01-13 Selective opioid receptor antagonist kappa

Country Status (32)

Country Link
US (2) US7709522B2 (https=)
EP (1) EP2252581B1 (https=)
JP (1) JP5345637B2 (https=)
KR (1) KR101172170B1 (https=)
CN (1) CN101925576B (https=)
AR (1) AR070158A1 (https=)
AU (1) AU2009206653B2 (https=)
BR (1) BRPI0907382B8 (https=)
CA (1) CA2713025C (https=)
CO (1) CO6290644A2 (https=)
CY (1) CY1113071T1 (https=)
DK (1) DK2252581T3 (https=)
DO (1) DOP2010000222A (https=)
EA (1) EA017484B1 (https=)
EC (1) ECSP10010365A (https=)
ES (1) ES2388708T3 (https=)
HR (1) HRP20120558T1 (https=)
IL (1) IL206038A (https=)
JO (1) JO2797B1 (https=)
MA (1) MA32751B1 (https=)
MX (1) MX2010007849A (https=)
MY (1) MY163014A (https=)
NZ (1) NZ586225A (https=)
PE (1) PE20091317A1 (https=)
PL (1) PL2252581T3 (https=)
PT (1) PT2252581E (https=)
SI (1) SI2252581T1 (https=)
TN (1) TN2010000306A1 (https=)
TW (1) TWI422369B (https=)
UA (1) UA100715C2 (https=)
WO (1) WO2009094260A1 (https=)
ZA (1) ZA201003908B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091439A1 (es) * 2008-01-22 2009-10-19 Takeda Pharmaceutical Compuestos triciclicos como antagonistas de crf
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
CA2911231C (en) * 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503646A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ,インコーポレーテッド うつ病の治療のための組成物及び方法
EP4463143A1 (en) * 2022-01-10 2024-11-20 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) * 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) * 2000-10-05 2004-04-08 モーラー,ハンス 選択的抗不安治療薬
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) * 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
CN1756746A (zh) * 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6-取代的烟酰胺衍生物
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
AU2005222640A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) * 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての4−(5−アミノメチル)−インドール−1−イルメチル)−ベンズアミド誘導体および関連化合物
CA2557794A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
PE20091317A1 (es) 2009-09-03
DK2252581T3 (da) 2012-07-16
US20100197669A1 (en) 2010-08-05
JP2011524850A (ja) 2011-09-08
CA2713025C (en) 2012-12-04
BRPI0907382B8 (pt) 2021-05-25
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
PL2252581T3 (pl) 2012-10-31
KR101172170B1 (ko) 2012-08-07
AU2009206653B2 (en) 2013-07-18
EA017484B1 (ru) 2012-12-28
BRPI0907382B1 (pt) 2020-03-10
US8173695B2 (en) 2012-05-08
UA100715C2 (ru) 2013-01-25
HK1146822A1 (en) 2011-07-15
WO2009094260A1 (en) 2009-07-30
SI2252581T1 (sl) 2012-09-28
DOP2010000222A (es) 2015-11-15
MA32751B1 (fr) 2011-11-01
NZ586225A (en) 2012-05-25
MY163014A (en) 2017-07-31
BRPI0907382A2 (pt) 2015-07-21
AR070158A1 (es) 2010-03-17
TN2010000306A1 (en) 2011-11-11
US20090186873A1 (en) 2009-07-23
KR20100095639A (ko) 2010-08-31
MX2010007849A (es) 2010-08-09
ZA201003908B (en) 2011-11-30
ES2388708T3 (es) 2012-10-17
CA2713025A1 (en) 2009-07-30
EP2252581B1 (en) 2012-06-20
JP5345637B2 (ja) 2013-11-20
PT2252581E (pt) 2012-08-31
EA201070877A1 (ru) 2010-12-30
CO6290644A2 (es) 2011-06-20
TW200936129A (en) 2009-09-01
IL206038A0 (en) 2010-11-30
HRP20120558T1 (hr) 2012-10-31
AU2009206653A1 (en) 2009-07-30
EP2252581A1 (en) 2010-11-24
CY1113071T1 (el) 2016-04-13
IL206038A (en) 2013-11-28
TWI422369B (zh) 2014-01-11
US7709522B2 (en) 2010-05-04
CN101925576A (zh) 2010-12-22

Similar Documents

Publication Publication Date Title
JO2797B1 (en) Selective opioid receptor antagonist kappa
HUS000512I2 (hu) Larotrektinib és/vagy gyógyszerészetileg elfogadható sói, elõnyösen larotrektinib-szulfát, beleértve a larotrektinib-hidrogénszulfátot
EP2350789A4 (en) PROXIMITY INTERFACE DEVICES, SYSTEMS AND METHOD
IL207835A0 (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2516311A4 (en) ELEVATOR, RAIL-GUIDE FASTENING BRACKET, ARRANGEMENT AND METHOD
IL208919A0 (en) Gpr119 receptor agonists
AP2012006276A0 (en) New CCR2 receptor antagonists and uses thereof.
SI2173737T1 (sl) Metoda za modulacijo gpr g proteinsko sklopljenega receptorja in izbrane spojine
ZA201007354B (en) Position-monitoring device for persons
EP2310019A4 (en) 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
GB2475009B (en) Method and system for storing,delivering and spooling preassembled pipelines
SG136908A1 (en) Guide device, particularly for use in welding
MX2010000724A (es) Metodo para reducir presion intracraneal.
EP2379140A4 (en) NEEDLE GUIDE
PL2300361T3 (pl) Urządzenie do wytwarzania wodoru
SI2174570T1 (sl) Kotalno izvlečno vodilo
EP2259609A4 (en) METHOD, SYSTEM AND DEVICE FOR CONVERSATION
IL207700A (en) Antagonists of receptor 3-aminoalkyl-1,4-diazepan-2-on melanocortin-5
PT2098669E (pt) Dispositivo de guiamento para porta de correr escamoteável
IL207701A0 (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
AP2011005547A0 (en) Method and device for core drilling.
PL2159337T3 (pl) Odpływ podłogowy, w szczególności do natrysków posadzkowych
PL2234751T3 (pl) Sposób i urządzenie do spawania konstrukcji siedzeniowych lub jednego siedzenia
ZA200807281B (en) CCR5 antagonists useful for treating HIV
TWM300668U (en) Improvement for steel bar feeding device